09:29 AM EDT, 03/13/2025 (MT Newswires) -- Mira Pharmaceuticals ( MIRA ) said Thursday it has expanded its pain management portfolio by developing topical formulation of Ketamir-2 to treat localized neuropathic and inflammatory pain.

The topical treatment of Ketamir-2 is developed for "slow release" to directly target the pain site, while also reducing systemic exposure and side effects, the company said, adding that potential applications include neuropathic pain conditions, inflammatory pain conditions, and nerve compression & musculoskeletal pain.

Mira said it is currently carrying out a phase 1 clinical study for the Ketamir-2 oral treatment for neuropathic pain.

MIRA shares were 3% higher ahead of Thursday's opening bell.